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Hypertension in end-stage renal disease. Patients with moderate
to severe renal disease have a very high incidence of hypertension.
In end-stage renal disease (ESRD) this is true regardless of the
nature of the underlying renal disease. Nevertheless, patients with
glomerular diseases and autosomal dominant polycyctic kidney
disease are particularly vulnerable. Evidence is presented that
ESRD hypertension is the result of extracellular volume expan-
sion, increased or inappropriate response of the renin-angiotensin
system and overactivity of the sympathetic system. In addition, the
role of endothelin-1, nitiric oxide and other vasodilators, and
abnormal ion channels in generating high blood pressure, is
considered.
Hypertension is a frequent complication of chronic renal
failure (ESRD). Numerous studies have established that
chronic parenchymal renal disease is the most common
cause of secondary hypertension, accounting for approxi-
mately 5% of all patients with hypertension [1]. Hyperten-
sion is an independent risk factor for ESRD, particularly in
African-Americans [2], but in many ESRD patients hyper-
tension develops as a result of the intrinsic renal malady.
For example, in chronic glomerular disease between 15%
and 80% of patients have hypertension; the range is
dependent on the underlying diagnosis, with the more
severe glomerular diseases having higher incidence of
hypertension [3, 4]. Virtually all patients with polycystic
kidneys (ADPKD) develop hypertension by the time
ESRD is present [5]. Tubulointerstitial disease is also
associated with a high incidence of hypertension once
ESRD is present [6].
PATHOPHYSIOLOGY
The model of uninephrectomy and salt-loading hyper-
tension in rats or other animals has been frequently used to
study the hypertension of chronic renal disease [7]. Al-
though this may be a valid paradigm of how expansion of
extracellular volume can cause hypertension, the pathogen-
esis of elevated blood pressure in ESRD is more complex.
Figure 1 shows factors that may influence blood pressure
regulation at any given time, and that in the case of ESRD
hypertension may be the result of multiple factors acting
simultaneously or individually. Ultimately, changes in car-
diac output or total peripheral resistance will determine
blood pressure levels. I will discuss some of the evidence
advanced to support a role of these factors in effecting
changes in blood pressure regulation.
SODIUM BALANCE
The overwhelming evidence obtained so far favors an
important role for extracellular volume and sodium balance
in the hypertension of ESRD. Early in the course of ESRD
plasma and extracellular fluid volumes are usually normal
[8, 9]. Moreover, in 50% or more of ADPKD patients,
hypertension is found at a time when changes in renal
function cannot be detected [10]. Nevertheless, with few
exceptions [11], most investigators [12, 13] have found
expanded blood or extracellular fluid volumes in ESRD
patients. Infusion of saline aggravates the hypertension of
ESRD patients by preferentially distributing to the intra-
vascular space, suggesting a similar fate for ingested salt
[14]. Moreover, various studies have shown a correlation
between exchangeable sodium and plasma volume, or
between the former and extracellular fluid volume in mild
to moderate renal insufficiency [9, 15] or in ESRD [12, 16,
17].
The precise mechanism by which volume expansion
increases blood pressure is unknown, but the autoregula-
tion theory of the pathogenesis of hypertension has been
advanced as an explanation (Fig. 2). Some evidence for this
sequence was initially obtained by Coleman, Granger and
Guyton [18]; however, experiments by others revealed a
more complex sequence of events in response to extracel-
lular volume expansion in anephric subjects as well as in
ESRD patients [19]. Kim and coworkers studied four
anephric and six ESRD patients on maintenance hemodi-
alysis [19]. The sequential study was carried out in the
following five phases: (1) stable, dry control weight; (2)
progressive volume expansion; (3) sustained volume expan-
sion; (4) during volume depletion; and (5) again at dry
control weight. Four hemodynamic patterns emerged from
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this study (Fig. 3). In two patients blood pressure did not
rise. In two patients in whom blood pressure increased,
only cardiac output rose without changes in total peripheral
resistance. In five patients total peripheral resistance rose
without alterations in cardiac output. In one anephric
patient, an initial rise in cardiac output without changes in
peripheral resistance was followed by a decrease in cardiac
output with marked elevation of peripheral resistance.
Since the level of expansion was identical in all patients,
these varied responses indicate different mechanisms of
response in different patients. Thus, as suggested in Figure
1, mechanisms other than whole body autoregulation,
including alterations in vasoactive substances or abnormal
ion channel function, play a role in the development of
hypertension in ESRD.
Evidence for the participation of multiple factors in the
genesis of ESRD hypertension may be gleaned from a
recent hemodialysis record study of 434 patients [20]. Equal
numbers of dialysis patients were receiving antihyperten-
sive therapy after one year of intense treatment, moreover,
hypertension persisted irrespective of whether interdialytic
weight fell, rose or stayed the same. In addition, the nature
of the underlying renal disease, a previous diagnosis of
hypertension, sex, or race, did not modify persistence of
hypertension and the need for treatment. These results also
point to the possibility that long-standing hypertension
and/or volume expansion may lead to damage of the
vasculature that makes it unresponsive to treatment. This
could result from either reduced production of vasodilator
substances or increased production of vasoconstrictor
agents.
Despite some of the controversial results it should be
clear that volume overload is to be avoided in the ESRD
patient, since it is clear that either directly or indirectly a
surfeit of sodium and water is deleterious.
SYMPATHETIC SYSTEM
Sympathetic overactivity has been demonstrated in es-
sential hypertension and renal diseases, including the ne-
phrotic syndrome [21]. Overactivity of this system augments
cardiac output and total peripheral resistance. This may
result from direct actions on cardiac and vascular receptors,
Fig. 1. Factors that may alter cardiac output
and total peripheral resistance in end-stage
renal disease, and thus raise blood pressure.
The role of abnormal channel function is
hypothetical, but it might contribute to either
an increase in peripheral resistance or an
increase in cardiac output (detailed in the text
and Fig. 3).
Fig. 2. Sequential response to volume expansion in anephric patients
and those with renal disease: the theory of whole-body autoregulation
[18].
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or by the influence on the release of renin and sodium
retention by the kidney. Plasma norepinephrine (NE) and
plasma renin activity (PRA, vide infra) are increased in
hypertensives with mild renal insufficiency as compared to
similarly renal-impaired normotensives or to normals [22].
Although the value of NE plasma levels to assess sympa-
thetic activity has been questioned, Converse and his
collaborators demonstrated that bilateral nephrectomy
abolishes increased sympathetic discharge, lowers calf vas-
cular resistance and reduces blood pressure in ESRD [23].
Of interest is the demonstration of a reduced threshold for
the pressor response to NE in both normotensive and
hypertensive patients with mild renal insufficiency [24].
Moreover, administration of debrisoquin, a post-ganglionic
sympathetic blocker, significantly reduced blood pressure
in hypertensive dialysis patients, but not in controls or
normotensive dialysis patients [25].
RENIN-ANGIOTENSIN SYSTEM
Patients with mild to moderate renal insufficiency exhibit
elevated PRA and plasma angiotensin II concentrations
that correlate with blood pressure [1]. Administration of
saralasin to hypertensive patients with early renal disease
results in a significant drop in blood pressure that is
proportional to basal PRA activity [26]. Angiotensin I
converting enzyme inhibitors (ACEI) and beta blockers can
also lower renal renin secretion, and have similar antihy-
pertensive effects in patients with mild to moderate renal
insufficiency as a result of various non-diabetic chronic
nephropathies [27]. The majority of hypertensive patients
with ESRD attain normotension or exhibit reduced blood
pressure in response to dry weight attainment with dialysis.
In these subjects plasma renin and angiotensin II levels are
within normal limits, but these are inappropriately elevated
in relation to exchangeable sodium [28].
By contrast, a group of ESRD patients who do not
respond to sodium removal have high renin and angioten-
sin II levels that correlate with the hypertension [29]. Blood
pressure in this group of patients is reduced or normalized
in response to saralasin or ACEI [30]. The strong relation-
ship between PRA, angiotensin II and blood pressure in
many ESRD patients lends support to an important role of
the renin-angiotensin system (RAS) in the genesis of
hypertension.
A relatively unexplored but critical aspect of the RAS in
humans is the presence of its components in the tissues of
many organs, including blood vessels. Renin and angio-
tensinogen may be taken up from the plasma or locally
synthesized in blood vessels. Since angiotensin II is capable
of releasing NE from nerve endings, it could effect smooth
muscle contraction either by its own direct action or
through NE. It is also known that angiotensin II is capable
of inducing vascular smooth muscle cell hypertrophy, and
thus its long-term effects could alter the vascular response
to antihypertensive treatment. For example, angiotensin II
could be responsible in part for the loss of compliance of
the aorta and other large vessels. This would influence the
development of systolic hypertension that would cause
further vascular damage and stiffening. We have shown in
an experimental model of hypertension (interrenal aortic
coarctation) that the aorta above the constriction, which is
exposed to hypertension and is distended, exhibits up-
regulation of the angiotensin II type 1 (AT1) receptor
mRNA and the expression of the receptor protein [31].
Over-expression of AT1 receptors would lead “normal”
levels of angiotensin II to bind in greater amounts and exert
Fig. 3. Different responses to salt and water
loading leading to hypertension in anephric
and ESRD patients [19].
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a greater pressor effect. It would also explain why exoge-
nous infusion of angiotensin II does not increase vascular
reactivity in ESRD patients [24]. A detailed analysis of
these aspects in ESRD patients remains to be performed.
ENDOTHELINS
Endothelin-1 (ET-1) has been implicated in the genesis
of hypertension in chronic renal failure. Patients with
ESRD or reduced nephron mass, as induced by unilateral
nephrectomy, have elevated circulating levels of the pep-
tide [32, 33]. The levels of ET-1 have correlated with
hypertension in some, but not all studies, but the use of
various assays makes comparisons among these studies
difficult [34]. Data exist supporting decreased renal clear-
ance of ET-1 in hypertension and, since the kidney is a
major site of ET-1 metabolism, reduced nephron mass
might prolong its half-life. In fact, ET-1 clearance is
reduced in patients with chronic renal failure since its
urinary excretion is lower than in normal controls [34].
Since most ET-1 is nephrogenous, the reduced clearance in
the presence of higher plasma levels suggests, but does not
prove, that it is secreted into the blood in the presence of
renal disease. A proposal as to how ET-1 may influence
blood pressure in the presence of mild to moderate reduc-
tions in renal function is shown in Figure 4.
NITRIC OXIDE
Evidence for a role of nitric oxide (NO) in experimental
one-kidney, one-clip hypertension is of interest since this
model resembles one of the hemodynamic responses to salt
loading in anephric or ESRD patients. The onset of
hypertension in this model is mediated by an increase in
cardiac output, but eventually total peripheral resistance is
elevated (whole body autoregulation) [7]. Upon removal of
the clip, blood pressure and cardiac output fall and a
natriuresis and diuresis ensue. Saline infusion delays the
hemodynamic recuperation, but does not prevent it, indi-
cating a multifactorial mechanism in the genesis of the
hypertension. A number of vasoactive substances have
been considered mediators (including the RAS, kallikrein-
kinin system, prostaglandins, and platelet activating factor)
of the response, but evidence in support of such a role has
not been forthcoming. On the other hand, inhibition of NO
synthesis prevents the reversal of hypertension upon clip
removal, and a sulfhydryl group donor (N-acetyl-L-cys-
teine) that protects NO from free radical destruction
potentiates the effect of unclipping [7].
Experimental inflammatory renal diseases, such as glo-
merulonephritis, have been shown to increase NO produc-
tion while renal ablation or glomerulosclerosis reduce
production of NO and excretion of urine nitrates [35].
Patients with mild, essential salt-sensitive hypertension, if
salt loaded, will respond with an increased renal vascular
resistance and impaired ability to produce NO by the renal
circulation compared to salt-resistant patients [36]. Re-
cently, it has been shown that vasodilation to acetylcholine
is reduced in salt-sensitive hypertensive patients, even on a
restricted salt diet [37] Moreover, salt-sensitive rats (Dahl-
Rapp and Dahl) have a genetic defect in nitrosovasodila-
tion, emphasizing the importance of NO in extracellular
volume regulation. Unfortunately, data are not available to
shed light on the role of NO in the hypertension of ESRD
or anephric patients [37].
OTHER VASODEPRESSORS
Few studies have examined the role of prostaglandin and
the kallikrein-kinin system in the genesis of hypertension in
early- and late-stage renal disease, but the results are
inconclusive. Theoretically, compounds that reduce vascu-
lar tone may help counteract the vasoconstrictive effects of
constrictor agents, such as angiotensin II, norepinephrine
and endothelin-1. Attempts to measure in urine and blood
the concentration of these compounds have revealed
ranges that run the gamut from low to high. Equally unclear
is the role of atrial natriuretic peptide in the hypertension
Fig. 4. Endothelin-1 (ET-1) can contribute to
hypertension in several ways. In this
hypothetical proposal by Markewitz and Kohan
[34], it is suggested that the development of
excessive responsiveness to the peptide may
arise from either an increased number of
receptor or a decreased intrarenal degradation
of ET-1. It is unclear if the kidney secretes ET-
1 into the circulation in chronic renal disease.
Equally unclear is whether ET-1 is a cause of
hypertension or if its high levels in ESRD
represent endothelial injury induced by
hypertension (see text). Paradoxically, the
contribution of ET-1 to ESRD hypertension
might include reversal of its effects on inner
medullary collecting duct (IMCD) to inhibit
sodium and water reabsorption. This could
result from an alteraltion in receptor number or
sensitivity induced by the chronic disease state
effect on the IMCD.
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of ESRD. This peptide is frequently high in ESRD patients
and bears little correlation to the level of blood pressure.
ABNORMAL CHANNELS
Arteries of rats with hypertension exhibit an enhanced
K1 efflux. A distinct K1 channel type in vascular smooth
muscle cell membranes has been identified that is the
pathway for the increased K1 current when these cells are
exposed to high pressure [38]. This is considered “a univer-
sal finding” of hypertension [39]. Recent studies support
that the ion channel represents a Ca21-sensitive K1 chan-
nel (KCa channel) that opens as a result of sudden stretch
of arterial smooth muscle [40]. Opening of these channels
would favor a loss of K1 from the cell, hyperpolarization
that would reduce voltage-dependent calcium influx and
relaxation of vascular muscle. Hypertension increases the
expression of KCa channels, which increases the density of
channel pathways, permitting compensatory K1 efflux. The
effect of hypertension on the Ca21-sensitive K1 channel
persists in arteries removed from their hypertensive envi-
ronment [41]. Moreover, pharmacological normalization of
hypertension in genetically hypertensive rats reduces the
KCa current in arterial myocytes within two weeks [42].
Studies to determine the role of Ca21-sensitive K1 chan-
nels in the hypertension of ESRD or anephric patients
would be of great interest. It is evident that in individuals
who develop hypertension, these channels curtail, but do
not prevent hypertension. Blockade of the channels in vitro
causes intense vasoconstriction in hypertensive but not in
normotensive arteries, suggesting that their principal role is
to prevent excessive rises in blood pressure in the chronic
phase of hypertension [43]. It is therefore possible that
hypertensive subjects have abnormal channels or abnormal
signaling pathways through the channels. In ESRD, sub-
stances that are non-dialyzable or whose release depends
on volume expansion might be responsible for blocking the
channels and either worsening hypertension or making it
resistant to therapy. Alternatively, the pre- or post-dialytic
environment may down-regulate the gene(s) encoding the
channel’s a and b subunits, reduce the number of channels
and make patients erratically responsive to medication,
susceptible to hypotension, or both. This could lead to
excessive dependence on saline infusion during dialysis and
perpetuate periods of stretch and relaxation that may
further complicate the control of hypertension in the
ESRD patient.
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